Xenetic Biosciences, Inc. Reports Second Quarter 2025 Financial Results
Xenetic Biosciences (NASDAQ:XBIO) reported its Q2 2025 financial results, highlighting key developments in its immuno-oncology programs. The company has expanded its strategic partnership with The Scripps Research Institute to advance DNase I combination therapy with CAR T-cells. Through collaboration with PeriNess, Xenetic initiated clinical studies exploring DNase I combinations with anti-CD19 CAR T cells for lymphoma and with FOLFIRINOX for pancreatic cancer.
Financial results showed a net loss of $0.7 million for Q2 2025, with decreased R&D expenses of $0.7 million (down 29.7% YoY) and reduced G&A expenses of $0.7 million (down 41.8% YoY). The company maintained a cash position of $4.8 million at quarter-end.
Xenetic Biosciences (NASDAQ:XBIO) ha comunicato i risultati finanziari del Q2 2025, evidenziando sviluppi chiave nei suoi programmi di immuno-oncologia. L'azienda ha ampliato la partnership strategica con The Scripps Research Institute per portare avanti la terapia combinata DNase I con cellule CAR T. In collaborazione con PeriNess, Xenetic ha avviato studi clinici che esplorano le combinazioni di DNase I con cellule CAR T anti-CD19 per il linfoma e con FOLFIRINOX per il cancro del pancreas.
I risultati finanziari mostrano una perdita netta di $0.7 milioni per il Q2 2025, con una riduzione delle spese in R&S di $0.7 milioni (in calo del 29,7% su base annua) e una diminuzione delle spese G&A di $0.7 milioni (in calo del 41,8% su base annua). L'azienda ha mantenuto una posizione di cassa di $4.8 milioni alla chiusura del trimestre.
Xenetic Biosciences (NASDAQ:XBIO) inform贸 sus resultados financieros del Q2 2025, destacando avances en sus programas de inmuno-oncolog铆a. La compa帽铆a ha ampliado su alianza estrat茅gica con The Scripps Research Institute para avanzar en la terapia combinada con DNase I y c茅lulas CAR T. En colaboraci贸n con PeriNess, Xenetic inici贸 estudios cl铆nicos que exploran combinaciones de DNase I con c茅lulas CAR T anti-CD19 para linfoma y con FOLFIRINOX para c谩ncer de p谩ncreas.
Los resultados financieros mostraron una p茅rdida neta de $0.7 millones en el Q2 2025, con gastos de I+D reducidos en $0.7 millones (鈭�29,7% interanual) y gastos G&A disminuidos en $0.7 millones (鈭�41,8% interanual). La compa帽铆a mantuvo una posici贸n de efectivo de $4.8 millones al cierre del trimestre.
Xenetic Biosciences (NASDAQ:XBIO)電� 2025雲� 2攵勱赴 鞁れ爜鞚� 氚滍憸頃橂┌ 氅挫棴頃晹 頂勲攴鸽灗鞚� 欤检殧 歆勳爠鞚� 臧曥“頄堨姷雼堧嫟. 須岇偓電� The Scripps Research Institute鞕�鞚� 鞝勲灥鞝� 韺岉姼雱堨嫮鞚� 頇曤寑頃� DNase I瓿� CAR T 靹疙彫鞚� 氤戩毄鞖旊矔鞚� 於旍頃橁碃 鞛堨姷雼堧嫟. PeriNess鞕�鞚� 順戨牓鞚� 韱淀暣 Xenetic鞚� 毽柬攧膦呾潉 鞙勴暅 anti-CD19 CAR T 靹疙彫鞕�鞚� DNase I 氤戩毄 氚� 旆岇灔鞎旍潉 鞙勴暅 FOLFIRINOX鞕�鞚� 氤戩毄鞚� 韮愳儔頃橂姅 鞛勳儊 鞐瓣惮毳� 鞁滌瀾頄堨姷雼堧嫟.
鞛 靹标臣搿滊姅 2025雲� 2攵勱赴 靾滌啇鞁� $0.7 million鞚� 旮半頄堨溂氅�, 鞐瓣惮臧滊皽牍勲姅 $0.7 million 臧愳唽(鞝勲厔 霃欔赴 雽�牍� 29.7% 臧愳唽), 鞚茧皹甏�毽箘(G&A)電� $0.7 million 臧愳唽(鞝勲厔 霃欔赴 雽�牍� 41.8% 臧愳唽)頄堨姷雼堧嫟. 攵勱赴 毵� 順勱笀 氤挫湢鞎§潃 $4.8 million鞚� 鞙犾頄堨姷雼堧嫟.
Xenetic Biosciences (NASDAQ:XBIO) a publi茅 ses r茅sultats financiers du 2e trimestre 2025 en soulignant des avanc茅es cl茅s dans ses programmes d'immuno鈥憃ncologie. La soci茅t茅 a 茅largi son partenariat strat茅gique avec The Scripps Research Institute pour faire progresser la th茅rapie combin茅e DNase I avec des cellules CAR鈥慣. En collaboration avec PeriNess, Xenetic a lanc茅 des 茅tudes cliniques explorant les combinaisons de DNase I avec des cellules CAR鈥慣 anti鈥慍D19 pour les lymphomes et avec le FOLFIRINOX pour le cancer du pancr茅as.
Les r茅sultats financiers ont montr茅 une perte nette de 0,7 million de $ pour le 2e trimestre 2025, avec des d茅penses de R&D r茅duites de 0,7 million de $ (鈭�29,7% en glissement annuel) et des frais G&A diminu茅s de 0,7 million de $ (鈭�41,8% en glissement annuel). La soci茅t茅 disposait d'une tr茅sorerie de 4,8 millions de $ 脿 la cl么ture du trimestre.
Xenetic Biosciences (NASDAQ:XBIO) ver枚ffentlichte die Finanzergebnisse f眉r das 2. Quartal 2025 und hob wichtige Entwicklungen in seinen Immunonkologie鈥慞rogrammen hervor. Das Unternehmen hat seine strategische Partnerschaft mit The Scripps Research Institute ausgeweitet, um die DNase鈥慖鈥慘ombinationstherapie mit CAR鈥慣鈥慫ellen voranzutreiben. In Zusammenarbeit mit PeriNess hat Xenetic klinische Studien initiiert, die DNase鈥慖鈥慘ombinationen mit anti鈥慍D19 CAR鈥慣鈥慫ellen bei Lymphomen und mit FOLFIRINOX bei Bauchspeicheldr眉senkrebs untersuchen.
Die Finanzzahlen wiesen einen Nettoverlust von $0,7 Millionen im Q2 2025 aus; die F&E鈥慉ufwendungen sanken um $0,7 Millionen (鈭�29,7% gg眉. Vorjahr) und die Verwaltungsaufwendungen (G&A) verringerten sich um $0,7 Millionen (鈭�41,8% gg眉. Vorjahr). Zum Quartalsende verf眉gte das Unternehmen 眉ber eine Barmittelposition von $4,8 Millionen.
- Expanded strategic partnership with The Scripps Research Institute for DNase I/CAR T-cell therapy development
- Initiated two clinical studies through PeriNess collaboration
- R&D expenses decreased by 29.7% year-over-year
- G&A expenses reduced by 41.8% compared to Q2 2024
- Maintained $4.8 million cash position for operations
- Reported net loss of $0.7 million in Q2 2025
- Still in early clinical development stages with no approved products
Insights
Xenetic's Q2 showed strategic progress in DNase platform development despite reduced losses, with $4.8M cash runway supporting continued R&D advancement.
Xenetic Biosciences reported their Q2 2025 results with several noteworthy developments in their DNase-based technology platform. The company has expanded its collaboration with The Scripps Research Institute to advance their innovative approach combining systemic DNase I with CAR T-cell therapies - a potentially significant advancement for treating difficult cancers where CAR T efficacy has been limited.
The company's partnership with PeriNess continues to bear fruit with two clinical studies now underway: one exploring DNase I with anti-CD19 CAR T cells in large B cell lymphoma and another testing DNase I with FOLFIRINOX chemotherapy in pancreatic cancer. These studies represent critical translational steps from preclinical to clinical validation.
Financially, Xenetic has shown improved cost management with R&D expenses decreasing by
The DNase platform's mechanism targeting the neutrophil extracellular traps (NETs) that shield tumors represents an innovative approach to enhance immune cell infiltration. The advancement toward IND filing and Phase 1 trials indicates progression along the biotech value creation pathway, though several regulatory hurdles remain before clinical validation.
Most encouraging is Xenetic's multi-pronged approach - testing DNase I in combination with various treatment modalities (immunotherapy, chemotherapy, radiotherapy, and CAR T) - which significantly expands potential applications while diversifying clinical risk across multiple indications.
Expanded strategic partnership with The Scripps Research Institute to advance proof-of-concept studies and further develop its program combining systemic DNase I with CAR T-cell therapies
Ended the quarter with
FRAMINGHAM, MA / / August 13, 2025 / (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, today reported its financial results for the second quarter 2025.
Recent Highlights
Expanded its collaboration with The Scripps Research Institute ("TSRI") to advance the development of the Company's development program evaluating the combination of systemic DNase I and CAR T-cell therapies;
Announced advancements from its collaboration partner, PeriNess Ltd. ("PeriNess") including:
Entered into a Clinical Study Agreement to support an exploratory clinical study of DNase I in combination with anti-CD19 CAR T cells in patients with large B cell lymphoma;
Commenced patient dosing in an exploratory clinical study of systemic DNase I in combination with FOLFIRINOX for the first line treatment of unresectable, locally advanced or metastatic pancreatic cancer at Bnei Zion Medical Center; and
Continued pursuit of other strategic collaborations to advance the Company's technology.
"We continue to set a strong foundation that we believe positions us for success as we advance our systemic DNase I in combination with immunotherapy, chemotherapy, and radiotherapy across various oncology indications where there remains significant unmet need. We continue to work with our partners and believe the data and information will be invaluable as we look to realize the full potential of our DNase platform technology. Looking ahead, we remain focused on building momentum across all fronts and driving development toward an IND and Phase 1 clinical trial," commented James Parslow, Interim Chief Executive Officer and Chief Financial Officer of Xenetic.
Xenetic continues to advance its DNase-based technology towards Phase 1 clinical development for the treatment of pancreatic carcinoma and other locally advanced or metastatic solid tumors. Preclinical proof-of-concept studies combining DNase I with chemotherapy, immunotherapies, and CAR-T therapy in hematological and solid tumor and metastatic cancer models have been completed. Building on proof-of-concept success, the program has now advanced to mechanism-of-action and translational studies in preparation for a Phase 1 clinical trial.
Additionally, as previously announced in December 2024, Xenetic entered into a Clinical Trial Services Agreement with PeriNess, under which PeriNess will lead in the regulatory approval, operational execution and management of potential exploratory, investigator initiated studies of recombinant DNase as an adjunctive treatment in patients with pancreatic carcinoma and other locally advanced or metastatic solid tumors receiving chemotherapy and immunotherapy in Israeli medical centers.
Summary of Financial Results for Second Quarter 2025
Net loss for the quarter ended June 30, 2025 was approximately
The Company ended the quarter with approximately
About Xenetic Biosciences
Xenetic Biosciences, Inc. is a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers. The Company's DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in cancer progression. Xenetic is currently focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and locally advanced or metastatic solid tumors.
For more information, please visit the Company's website at and connect on , , and .
Forward-Looking Statements
This press release contains forward-looking statements that we intend to be subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release other than statements of historical facts may constitute forward-looking statements within the meaning of the federal securities laws. These statements can be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "intends," "estimates," "remain," "focus", "confidence in", "potential", and other words of similar meaning, including, but not limited to, all statements regarding expectations for our DNase-base oncology platform, including statements regarding: (a) advancing our DNase-based oncology program towards Phase 1 clinical development for the treatment of pancreatic carcinoma and other locally advanced or metastatic solid tumors and our focus on building momentum and driving development toward an IND and Phase I clinical trial, (b) setting a strong foundation that we believe positions us for success as we advance DNase I in combination with various types of therapy and (c) working with our partners and our belief regarding the data and information as we look to realize the full potential of DNase. Any forward-looking statements contained herein are based on current expectations and are subject to a number of risks and uncertainties. Many factors could cause our actual activities, performance, achievements, or results to differ materially from the activities and results anticipated in forward-looking statements. Important factors that could cause actual activities, performance, achievements, or results to differ materially from such plans, estimates or expectations include, among others, (1) unexpected costs, charges or expenses resulting from our manufacturing and collaboration agreements; (2) unexpected costs, charges or expenses resulting from the licensing of the DNase platform; (3) uncertainty of the expected financial performance of the Company following the licensing of the DNase platform; (4) failure to realize the anticipated potential of the DNase or PolyXen technologies; (5) the ability of the Company to obtain funding and implement its business strategy; and (6) other risk factors as detailed from time to time in the Company's reports filed with the SEC, including its annual report on Form 10-K, periodic quarterly reports on Form 10-Q, current reports on Form 8-K and other documents filed with the SEC. The foregoing list of important factors is not exclusive. In addition, forward-looking statements may also be adversely affected by general market factors, general economic and business conditions, including potential adverse effects of public health issues, and geopolitical events, such as the conflicts in Ukraine and in the Middle East, on economic activity, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new product candidates and indications, manufacturing issues that may arise, patent positions, litigation, and shareholder activism, among other factors. The forward-looking statements contained in this press release speak only as of the date the statements were made, and the Company does not undertake any obligation to update forward-looking statements, except as required by law.
Contact:
JTC Team, LLC
Jenene Thomas
(908) 824-0775
[email protected]
SOURCE: Xenetic Biosciences, Inc.
View the original on ACCESS Newswire
FAQ
What were Xenetic Biosciences (XBIO) key financial results for Q2 2025?
What progress has XBIO made in its DNase I development program?
How has Xenetic Biosciences reduced its expenses in Q2 2025?
What clinical trials is Xenetic Biosciences currently conducting?
What is Xenetic Biosciences' current cash position and burn rate?
